Residual Disease Clinical Trial
Official title:
Comparison of R0 Resection Rate Between Cold Snare Polypectomy, Cold Endoscopic Mucosal Resection and Hot Endoscopic Mucosal Resection for 1-2 cm Colorectal Sessile Serrated Lesions: a Randomized Control Trial
Colorectal cancer is the most prevalent cancer and the third cancer related death in Taiwan. Adenoma is a precancerous lesion of colorectal cancer. Using colonoscopy to detect and remove the adenoma has a chance to prevent colorectal cancer development. In the resection of colorectal polyps, for medium and large polyps that are more than one centimeter and less than two centimeters, because these polyps are at risk of cancer, they currently use hot-snaring polypectomy or more advanced endoscopic mucosal resection. Resection of such tumors ensures that a sufficient depth of resection and a high complete resection rate (R0 resection) are achieved. Flat serrated adenoma (sessile serrated lesion) is a special adenoma that accounts for 10-12% of all colorectal polyps. Different from traditional adenomas, flat serrated adenomas within two centimeters in size have very little chance of becoming cancerous. And we know that on removal of medium and large polyps of 10-20mm, compared with the cold snaring polypectomy, the postoperative bleeding of the hot-snaring polypectomy technique is higher. Therefore, when removing low-risk polyps such as flat serrated adenomas, we may choose using a non-energized technique with low complications and we then would like to know whether the complete resection rate can be achieved by using the non-energized technique in the resection of a flat serrated adenoma of 10-20 mm, despite the large size, and compare the success rate and complications with traditional hot snaring polypectomy.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | September 1, 2025 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: 1. Age older than 20 years old 2. Indicated for colonoscopy and willing to receive colonoscopy examination and polyp resection? 3. Any Sessile serrated adenoma size between 10-20mm was found during the examination? Exclusion Criteria: 1. Age younger than 20 years old 2. Contraindication for colonoscopy or polypectomy (Such as recent acute myocardial infarction, pulmonary embolism ,coagulopathy..) |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei | Taiwan (roc) |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | R0 resection rate | The margin of the resected specimen showed no adenoma involvement | within 14 days | |
Secondary | Delayed post-polypectomy bleeding | Bleeding occurs delayed from several hours to weeks after the polypectomy | within 14 days | |
Secondary | Immediate post-polypectomy bleeding | Bleeding occur immediately after the polypectomy | within 24 hours | |
Secondary | Bowel perforation rate | Bowel perforation occurs after colonoscopy | within 14 days | |
Secondary | Number of hemoclips per polypectomy | Total number of hemoclips used after each polypectomy for hemostasis | within 1 hour | |
Secondary | Emergency department visit | Patient visit ER after polypectomy for any complication | within 14 days | |
Secondary | Procedure time | Total time spent for polypectomy and hemostasis technique | within 1 hour |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04674306 -
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
|
Early Phase 1 | |
Active, not recruiting |
NCT03189576 -
Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
|
N/A | |
Completed |
NCT03093207 -
Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02389517 -
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
|
Phase 2 | |
Not yet recruiting |
NCT06134375 -
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
|
Phase 1/Phase 2 | |
Recruiting |
NCT03945721 -
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
|
Phase 1 | |
Active, not recruiting |
NCT03384914 -
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
|
Phase 2 |